Related Experiment Video

Updated: Jan 6, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

761

Genetic Prediction of Erectile Dysfunction Caused by Statins Among Malaysian Cardiac Patients

Naam Bahjat Ahmed Adeeb1,2, Hadeer Akram Al-Ani3, Nur Aizati Athirah Daud1,4

  • 1Human Genome Centre, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kota Bharu 16150, Kelantan, Malaysia.

International Journal of Molecular Sciences
|September 13, 2025
PubMed

Insights

Statin use may increase erectile dysfunction (ED) risk in males, particularly impacting NR2F2-AS1 and NOS3 genes. Atorvastatin showed varied effects, with CYP17A1 most affected.

Area of Science:

  • Cardiovascular Genetics
  • Pharmacogenomics
  • Urology

Background:

  • Erectile dysfunction (ED) is prevalent in patients with cardiovascular diseases and diabetes mellitus.
  • Emerging evidence suggests statin therapy may elevate the risk of developing ED.
  • Genetic predispositions are increasingly recognized as contributing factors to ED.

Purpose of the Study:

  • To investigate the association between specific gene polymorphisms and ED in Malaysian cardiac patients undergoing statin therapy.
  • To explore the impact of statins, particularly atorvastatin, on ED risk through genetic analysis.
  • To identify novel genetic factors influencing ED in males using statins.

Main Methods:

  • Cross-sectional genetic study involving 246 cardiac patients.
  • Patients categorized into four groups based on statin use, ED status, and diabetes.
  • Analysis of six candidate genes (CYP19A1, CYP17A1, SIM1, TP53, NR2F2, NOS3) and their polymorphisms related to ED.

Main Results:

  • Statin therapy demonstrated a negative impact on ED, significantly affecting NR2F2-AS1 and NOS3 gene variants.
  • Atorvastatin exhibited differential effects across all investigated genes, with the most pronounced impact on CYP17A1 and the least on CYP19A1.
  • Specific gene polymorphisms were identified as potential contributors to ED in the context of statin use.

Conclusions:

  • This study highlights significant genetic factors influencing ED in Malaysian males using statins.
  • Findings suggest that NR2F2-AS1 and NOS3 are key genes affected by statin therapy in relation to ED.
  • The differential impact of atorvastatin on various genes provides insights into personalized medicine approaches for ED management.

Keywords:
CYP17A1CYP19A1NOS3NR2F2-AS1atorvastatinerectile dysfunction

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.1K

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
843
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
234
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
15.2K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
290
Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
1.4K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
563